NL Industries, Inc. (ticker: NL) has been on the radar for value-oriented investors like us everyday folks who aren’t Wall Street pros. This small-cap holding company, with stakes in specialty chemicals via its interest in Kronos Worldwide (a major titanium dioxide producer) and security products through CompX International, plus some real estate, has shown real resilience amid industry cycles. Over the past decade, NL’s stock has traded in a wide range—from annual lows dipping below $2 in tougher years to highs above $16 during booms—reflecting the volatility of TiO2 pigment prices, which drive much of its fortunes. Recently closing around current levels, the shares are hovering in the mid-single digits, but with strong 2024 profitability, insider buying, and a rock-solid balance sheet, it’s worth digging into whether this could be a hidden gem or just another cyclical play.
Revenue Growth and Operational Efficiency
Let’s start with the top line, because revenue tells us if the business engine is revving. From $109 million in 2016, NL’s sales climbed steadily to a peak of $167 million in 2022—a hefty 53% increase over six years—fueled by surging TiO2 demand during post-COVID construction and manufacturing rebounds. Think about it: titanium dioxide is everywhere in paints, coatings, and plastics, and global supply tightness from energy costs and raw material shortages supercharged prices in 2021-2022. Revenue per employee also rose impressively, from about $211,000 in 2016 to $286,000 in 2024 (up 36%), signaling smarter operations even as headcount held steady around 500-600 folks. That’s key for us retail investors—it shows management squeezing more productivity without bloating payroll.
But cycles bite: 2023 saw a 3% drop to $161 million amid softening TiO2 prices and weaker industrial demand, followed by a sharper 10% decline to $146 million in 2024. Revenue per share mirrored this, falling from $3.41 in 2022 to $2.99 in 2024 (-12%). Still, these aren’t catastrophe levels; NL’s diversified holdings (CompX’s locks and security components provide steadier cash) cushioned the blow. Looking ahead, analyst forecasts in the data don’t extend detailed projections beyond 2024, but the pattern suggests stabilization if TiO2 markets firm up—perhaps with green energy pushes boosting pigment needs for solar panels and EVs.
Gross margins hovered in the low-to-mid 30% range (28-32%), dipping to 28.3% in 2024 from 30.5% in 2023 (-7%). This metric matters because it strips out overhead to show core pricing power; the slight erosion likely ties to higher input costs, but it’s held up better than pure-play chemical peers hammered by inflation.
Profitability Swings: The TiO2 Rollercoaster
Earnings are where NL gets exciting—and nerve-wracking. Earnings per share (EPS) exploded from $0.31 in 2016 to $2.38 in 2017 (+668%!), thanks to a one-time tax benefit and TiO2 price spikes. Then 2018’s -$0.84 EPS (-135%) crushed it, as pigment prices tanked amid oversupply and trade tensions (remember U.S.-China tariffs hitting chemicals?). Recovery followed: 2024 delivered $1.38 EPS, up from a measly -$0.05 in 2023 (a whopping turnaround), with EBT margin rocketing to 57.1% from -4%—the highest since 2017’s 100% outlier.
Net income swung wildly too: $118 million in 2017 to a $39 million loss in 2018 (-133%), then stabilizing around $16-69 million lately, hitting $69 million in 2024 (+11,800% from 2023’s $0.6 million). ROE, a favorite for gauging returns on shareholder money, peaked at 42% in 2017 but settled at a healthy 16.7% in 2024—double the prior year’s negative. This volatility correlates tightly with Kronos’ performance; NL’s ~30% stake there amplifies swings, but also upside. Major events like the 2020 COVID dip (revenue -8%) and 2021-22 boom (revenue +23% YoY) underscore this. Positively, free cash flow per share stayed robust at $0.60 in 2024 (from $0.73 prior, -18%), with total FCF at $29 million—vital for dividends or buybacks without debt reliance.
Balance Sheet: Fortress-Like Strength
Here’s where NL shines for conservative investors. Book value per share grew steadily from $3.99 in 2016 to $8.52 in 2024 (+114%), reflecting retained earnings despite payouts. Shareholders’ equity ballooned from $194 million to $416 million (+114%). Total debt? A laughable $0.5 million flat across years—peanuts. Better yet, net debt is deeply negative (net cash pile grew to -$183 million by 2024, meaning $183 million cash excess). Working capital surged to $147 million, up 22% from 2023.
Valuation ratios scream cheap: 2024 P/E at 5.6 (vs. historical average ~10), P/B 0.91 (trading below book—rare value signal), and EV/FCF 6.7. Compare to 2017’s frothy P/E 5.5 but sky-high multiples elsewhere. PS ratio at 2.6 feels fair given growth. Stock price tracked these: highs of $16 in 2017 with profits, lows ~$2.3 in 2020 COVID panic (despite solid book value), and 2024 range $5-$9.4 amid earnings rebound. Shares outstanding barely budged (48.7-48.8 million), so no dilution dilution risk.
Capex flipped positive to $3.6 million in 2024 (from negative/outsourcing trend), hinting at reinvestment—good for future growth.
Insider Activity: A Bullish Signal
No sells in sight, but early 2025 saw insiders scoop up ~13,000 shares for $91,000 total—a director grabbing 13,000 shares over two days (March 11-12) and the SVP/Treasurer adding 250. In a low-volume stock like NL, this screams confidence, especially post-2024 profit surge. Insiders putting skin in the game often precedes outperformance; zero sells since at least late 2024 reinforces no one’s fleeing.
Valuation and Market Outlook
At recent closes, NL trades at discounts to historical norms, with PB under 1 and low-single-digit P/E on strong EPS. Analyst price targets cluster tightly, implying roughly a -5% move from recent levels—conservative, perhaps baking in TiO2 uncertainty from China oversupply and slowing construction. High, mean, and low all align, suggesting limited volatility expected.
Stock price evolution ties directly to fundamentals: booms in 2017/2021-22 lifted highs 50-100%+ YoY on profit surges, while 2018/2023 lows reflected losses. Now, with ROA at 11.6% (best since 2017) and ROIC 10.2%, shares at ~mid-range of 2024 ($5-9) look undervalued if cycles turn.
Future Developments: Steady Growth Ahead?
Analysts’ lack of detailed 2025-2027 forecasts leaves room for optimism. If TiO2 prices stabilize (post-2024 weakness), revenue could rebound 10-15% toward $160-170 million, per historical patterns. Kronos’ efficiency drives (new plants, cost cuts) and CompX’s niche strength (airport security, firearms components) provide tailwinds. Expect EPS $1.00-1.50 range if margins hold 30-40%, supporting ROE >10%. Dividend? NL’s history of special payouts on cash hoards could resume. Risks: chemical downturns, like 2018’s tariff hit or 2023 slowdown.
Bottom line for us retail warriors: NL’s not flashy, but its cash fortress, insider buys, and cyclical upside make it a compelling hold/buy on dips. At current valuations, it’s priced for bad news already—watch TiO2 trends and Q1 2025 reports. If fundamentals correlate as before, shares could revisit $9 highs (50%+ upside). Do your homework, but this feels like patient money territory.
(Word count: 1,128)